Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML By Ogkologos - September 14, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PARADIGM study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann EMA Recommends Extension of Therapeutic Indications for Teclistamab MOST POPULAR FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for NSCLC with EGFR... September 24, 2024 Cancer Survivor Kicked Out Of Bridal Party Cause She Refused To... August 29, 2019 A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit... August 5, 2025 Are Cancer Patients Getting the Opioids They Need to Control Pain? September 16, 2020 Load more HOT NEWS Healthy 33-Year-Old Nurse Learned She Had Cervical Cancer and Breast Cancer... Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma Dabrafenib–Trametinib Combination Approved for Solid Tumors with BRAF Mutations Junk food marketing restrictions: so near and yet so far
